Test Price

2,800 AED

✅ Home Collection Available

LYRM4 Gene Combined Oxidative Phosphorylation Deficiency Type 19 Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced Genetic Test analyses the entire LYRM4 gene to identify pathogenic variants underlying Combined Oxidative Phosphorylation Deficiency Type 19 (COXPD19), a severe autosomal recessive mitochondrial disorder. Next Generation Sequencing (NGS) with >100x coverage ensures >99.9% sensitivity for all coding regions and splice junctions.

Feature	Our Test (LYRM4 NGS)	Closest Alternative (Panel/Exome)
Precision	99.9% sensitivity for LYRM4 variants; validated NGS with >100x coverage	Variable; may miss deep intronic or regulatory mutations
Methodology	Next Generation Sequencing (NGS) – targeted single-gene analysis	Broad NGS panel or whole exome sequencing
Turnaround Time	3 to 4 weeks	4 to 8 weeks

Physician Insight & Safety Protocols

“As a clinical geneticist, I emphasize that the LYRM4 NGS test provides definitive molecular diagnosis, but results must be interpreted in the context of full clinical and family history. Genetic counselling before and after testing is mandatory. Do not alter any treatments based solely on genetic results without consulting your physician.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Advisory

Do not discontinue prescribed medication without consulting your doctor. Genetic results are only one piece of the diagnostic puzzle; all management decisions must be made in partnership with your treating specialist.

Safety Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: Active severe infection requiring hospitalization, known severe coagulopathy contraindicating blood draw, inability to provide informed consent (guardian/legal representative must consent for minors).
ER Red Flags: If you experience excessive bleeding, fainting, or signs of infection (redness, swelling, fever) at the blood collection site after sample collection, seek immediate medical attention.
This test is not a standalone diagnostic tool; results must be correlated clinically. Genetic counselling is mandatory before testing.

Patient FAQ & Clinical Guidance

1. What is the LYRM4 gene NGS test?

The LYRM4 gene NGS test detects pathogenic variants causing Combined Oxidative Phosphorylation Deficiency Type 19, a severe progressive mitochondrial disorder. It analyses the entire coding region and splice junctions of the LYRM4 gene using high-throughput sequencing, ensuring >99.9% sensitivity for known mutations. Results guide accurate diagnosis, family risk assessment, and personalised management.

2. How is the test performed?

Sample collection requires a simple blood draw (3–5 mL whole blood) or a single drop of blood on an FTA card, performed by our VIP mobile phlebotomy team at your home, office, or hotel across the UAE. Extracted DNA is then processed through NGS technology in our ISO 9001:2015 certified laboratory, with results delivered in 3–4 weeks. A genetic counselling session is mandatory before sample collection to review family history and informed consent.

3. What do abnormal results mean?

Abnormal results indicate you carry two pathogenic variants (homozygous or compound heterozygous) in the LYRM4 gene, confirming the diagnosis of Combined Oxidative Phosphorylation Deficiency Type 19. This autosomal recessive condition affects cellular energy production, leading to multisystem involvement including neurological, cardiac, and hepatic symptoms. A positive result requires immediate multidisciplinary follow‑up; first‑degree relatives should consider carrier testing and genetic counselling.

UAE Regulatory & Data Privacy Adherence

This test is performed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified and operates under DHA Facility License No. 1143.

Clinical & Logistical Metadata

Test Name	LYRM4 Gene Combined Oxidative Phosphorylation Deficiency Type 19 Genetic Test
Price (AED)	2,800
Turnaround Time	3 to 4 weeks
Sample Type / Matrix	Peripheral whole blood (3–5 mL) or dried blood spot (FTA card)
Methodology Used	Next Generation Sequencing (NGS) – targeted single-gene analysis
ICD-10-CM Code	E88.49
LOINC Code	21636-6
DHA Facility License & Laboratory Address	License 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

💬 التحقق عبر الواتساب Verify via WhatsApp 📞 Call Team

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians

Related Tests

Genetic